The Cancer Letter

Inside information on cancer research and drug development

In Brief

Thyme Care secures $60M in series B funding to scale cancer care beyond the clinic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Thyme Care raised $60 million in series B funding, co-led by Town Hall Ventures and Foresite Capital and with participation from current investors Andreessen Horowitz Bio + Health, AlleyCorp, Casdin Capital, and Frist Cressey Ventures. The capital brings Thyme Care’s total capital raised to over $80 million (The Cancer Letter, Oct. 7, 2022). 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Turning the page: Projections for cancer care in the coming year

As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers. 
By Samyukta Mullangi
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account